A Survey of Recent Patents on CB2 Agonists in the Management of Pain
Abstract:Pain, a homeostatic and protective mechanism which can go awry in disease states and therefore needs treatment, is a complex and differentiated sensorial perception which may be classified as physiological, inflammatory and neuropathic. Chronic pain represents a major health problem throughout the world, thus several companies and researchers have embarked on the search for new drugs and targets to treat the disease. The different types of receptors in the CNS involved in the mediation of analgesia include the cannabinoid receptors: in particular, CB2 modulators seem to represent a new potential class of analgesic. This review covers recent patents and advances in CB2 agonist studies in the management of pain.
Keywords: Azacycloalkane Carboxamides; BOEHRINGER INGELHEIM; Biphenylmethyl Ethyl Ureas; CARA THERAPEUTICS; CB2 receptor ligands; CB2 receptors; Cannabinoid; chronic pain; inflammatory pain; neuropathic pain
Document Type: Research Article
Publication date: 2012-04-01
- Recent Patents on CNS Drug Discovery publishes review articles on recent patents in the field of CNS drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on CNS drug discovery is also included in the journal. The journal is essential reading for all researchers involved in CNS drug design and discovery.